OS Therapies Statistics
Total Valuation
OS Therapies has a market cap or net worth of $74.26 million. The enterprise value is $74.06 million.
| Market Cap | 74.26M |
| Enterprise Value | 74.06M |
Important Dates
The next estimated earnings date is Monday, November 16, 2026, before market open.
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OS Therapies has 46.13 million shares outstanding. The number of shares has increased by 125.88% in one year.
| Current Share Class | 46.13M |
| Shares Outstanding | 46.13M |
| Shares Change (YoY) | +125.88% |
| Shares Change (QoQ) | +13.52% |
| Owned by Insiders (%) | 11.99% |
| Owned by Institutions (%) | 6.29% |
| Float | 40.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 8.27 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18
| Current Ratio | 0.18 |
| Quick Ratio | 0.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -464.76 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -232.65% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 350.07% |
| Weighted Average Cost of Capital (WACC) | 0.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.87M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.86% in the last 52 weeks. The beta is -0.68, so OS Therapies's price volatility has been lower than the market average.
| Beta (5Y) | -0.68 |
| 52-Week Price Change | -17.86% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 43.28 |
| Average Volume (20 Days) | 747,599 |
Short Selling Information
The latest short interest is 2.11 million, so 4.58% of the outstanding shares have been sold short.
| Short Interest | 2.11M |
| Short Previous Month | 2.58M |
| Short % of Shares Out | 4.58% |
| Short % of Float | 5.26% |
| Short Ratio (days to cover) | 3.42 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.61M |
| Pretax Income | -39.37M |
| Net Income | -39.37M |
| EBITDA | -37.11M |
| EBIT | -37.61M |
| Earnings Per Share (EPS) | -$1.05 |
Balance Sheet
The company has $205,035 in cash and no debt, with a net cash position of $205,035 or $0.00 per share.
| Cash & Cash Equivalents | 205,035 |
| Total Debt | n/a |
| Net Cash | 205,035 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -10.84M |
| Book Value Per Share | -0.26 |
| Working Capital | -17.00M |
Cash Flow
| Operating Cash Flow | -18.53M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 499,752 |
| Net Borrowing | 1.84M |
| Free Cash Flow | -18.53M |
| FCF Per Share | -$0.40 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OS Therapies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -125.88% |
| Shareholder Yield | -125.88% |
| Earnings Yield | -53.35% |
| FCF Yield | -25.11% |
Analyst Forecast
The average price target for OS Therapies is $8.50, which is 427.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 427.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |